Vericel Corporation announced preliminary 2025 financial results with total revenue of $276 million, driven by MACI revenue of $239.5 million. The company achieved 23% fourth quarter revenue growth, 74% gross margin, and 26% adjusted EBITDA margin, with GAAP net income profitability for the second consecutive year. The company completed its MACI sales force expansion and initiated a clinical study for MACI Ankle, while maintaining $200 million in cash with no debt.

Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation for approximately $31 million in Q3 2025, reducing its stake while the biotech company reported strong quarterly revenue growth of 17%.

MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.

Vericel reported Q2 2025 revenue growth of 20% to $63.2 million, driven by strong MACI cartilage repair franchise performance. The company expanded gross margins to 74% and narrowed net loss per share, while preparing for potential market expansion into ankle cartilage repair.

Vericel Corporation reported strong financial results for the second quarter of 2024, with record revenue, MACI revenue growth, and significant margin expansion. The company also provided an update on the progress of its NexoBrid launch and raised its full-year profitability guidance.

The global regenerative medicine market is expected to grow from $31.90 billion in 2023 to $349.93 billion by 2033, driven by advancements in cell therapy, stem cell therapies, and tissue engineering. The musculoskeletal disorders segment is the fastest-growing application area.

Vericel Corp's Chief Legal Officer, Sean C. Flynn, has sold $782,700 worth of company stock as part of a prearranged trading plan. The transaction comes amid the company's strong financial performance and positive analyst coverage.

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

Throughout the last three months, 4 analysts have evaluated Vericel (NASDAQ:VCEL), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $54.0, a high estimate of $55.00, and a low estimate of $53.00. This current average has increased by 5.88% from the previous average price target of $51.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Vericel by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $55.00 $53.00 Samuel Brodovsky Truist Securities Maintains Buy $54.00 $54.00 Samuel Brodovsky Truist Securities Raises Buy $54.00 $51.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $53.00 $46.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com

Total Revenue Increased 25% to $51.3 Million

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.